Full Year 2023 Investor Presentation
113
Investor presentation
Full year 2023
International Operations at a glance.
Novo NordiskⓇ
Diabetes trend
Million
DKK
billion
19%
17%
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
MS
Full year 2023
Sales
(mDKK)
Growth²
Injectable GLP-1³
31,228
41%
250
100%
600
Rybelsus®
7,389
142%
Total GLP-1
38,617
53%
200
80%
38.5%¹
GLP-1
Total insulin4
37,230
0%
400
720
150
60%
Other Diabetes care5
1,987
-12%
Insulin
Diabetes care
77,834
20%
587
487
100
1.8%1
40%
Obesity care
8,315
47%
200
50
OAD
20%
Diabetes & Obesity
86,149
22%
9.0%¹
care
0
0
0%
2021
2030
Population with diabetes
Diabetes growth rate
2045
Nov
2018
Nov
2023
Rare disease?
Total
9,483
-24%
95,632
16%
-GLP-1 MS
-Insulin MS
OAD MS
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific; Source: International Diabetes
Federation: Diabetes Atlas 10th Edition 2021
1 CAGR calculated for 5-year period; Competitor insulin value market shares, as of
Nov 2023: Novo Nordisk 51%, Others 49%; Competitor GLP-1 value market shares, as
of Nov 2023: Novo Nordisk 71%, Other 29%; OAD: Oral anti-diabetic; MS: Market
share; Note: Market values are based on the list prices; Source: IQVIA MAT, Nov
2023 value figures
2 At Constant exchange rates; 3 Comprises Victoza®, Ozempic®;
4 Comprises TresibaⓇ, XultophyⓇ, Levemir®, RyzodegⓇ, Novo Mix®, FiaspⓇ and
NovoRapidⓇ; 5 Comprises Novo NormⓇ and needles; 6 Obesity care comprises
SaxendaⓇ and Wegovy®; 7 Comprises primarily NovoSeven®, Novo Eight®
NovoThirteen®, Refixia®, Esperoct®, Norditropin®, Vagifem® and ActivelleⓇView entire presentation